Next Generation of Integrin Therapeutics
Oncology, Fibrosis, NASH
We are developing a pipeline of novel, best-in-class agents that precisely target key mechanisms of cancer and fibrosis.
Integrin mediated activation of TGF-β is at the root of resistance to therapies in the cancer tumor micro-environment, fibrosis and NASH.
Integrins are vital components of the cell’s machinery to link the intracellular and extracellular environment, and essential aspects of cell behavior.
Studies have demonstrated their connection with several types of cancer, particularly during metastases and angiogenesis (Marelli et al., 2013).
Integrins represent cell surface receptors, and are in an ideal position to become pharmacological targets.